Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Enveric Biosciences (NASDAQ:ENVB) reported Q2 2025 financial results and significant progress in its neuroplastogenic drug development programs. The company's lead candidate, EB-003, demonstrated a novel dual mechanism of action targeting both 5-HT₂A and 5-HT₁B receptors, positioning it as a first-in-class therapeutic for mental health conditions.
Key developments include positive preclinical results in PTSD and chronic depression models, with EB-003 showing rapid extinction of fear responses and significant reduction in behavioral despair. The company is advancing toward an IND submission in early 2026. Financial results showed a net loss of $2.5 million for Q2 2025, with cash reserves of $2.8 million and additional fundraising of $4.9 million in H1 2025.
Enveric also strengthened its IP portfolio with new patent grants and allowances across multiple chemical classes, reinforcing its position in non-hallucinogenic neuroplastogenic compounds.
Enveric Biosciences (NASDAQ: ENVB) has secured a second U.S. patent allowance for its EVM401 Series, covering novel methylone-inspired compounds designed for mental health treatment. The patent, titled "Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives," focuses on non-hallucinogenic benzodioxole derivatives engineered to modulate neurotransmitters for neuropsychiatric disorders.
The compounds are structurally similar to methylone, which has shown positive Phase 2 results in PTSD treatment, but feature unique chemical structures enabling patent protection and potential repeat-dose outpatient care. Unlike methylone, which lacks composition patent exclusivity, Enveric's molecules are fully patentable and proprietary. The company will conduct further preclinical testing to evaluate safety, pharmacokinetics, and effectiveness against PTSD.
Enveric Biosciences (NASDAQ: ENVB) announced positive preclinical results for its lead drug candidate EB-003 in a PTSD model. The study demonstrated that EB-003 significantly decreased context-induced freezing behavior (p < 0.05) in fear-conditioned mice one hour after administration, matching the therapeutic effects of MDMA used as control.
The research, conducted by a third-party lab, utilized a well-established translational rodent model. CEO Joseph Tucker highlighted that current FDA-approved PTSD treatments (SSRIs) achieve only 20-30% full remission rates with delayed onset of benefits. EB-003, as a next-generation neuroplastogen, shows potential to enhance hippocampal neuroplasticity without causing hallucinations, potentially offering a breakthrough in PTSD treatment.
Enveric Biosciences (NASDAQ: ENVB) has announced new data revealing that its lead candidate EB-003 acts as an agonist of the serotonin receptor 5-HT1B, expanding its potential therapeutic applications. The compound demonstrated agonism of 5-HT1B with an EC50 of 110 nM, complementing its known partial agonist activity on the 5-HT2A receptor.
This discovery broadens EB-003's potential applications to include major depressive disorder, Parkinson's disease, migraines, and cluster headaches. The drug candidate is currently in preclinical development, with IND-enabling activities planned through 2025. Previous data had shown positive pharmacology, in vitro safety, and oral bioavailability, including therapeutically relevant brain exposure in rodent models.
Enveric Biosciences (NASDAQ: ENVB) has announced positive preclinical results for its lead drug candidate EB-003 in treating severe chronic depression. The drug demonstrated statistically significant improvements in the Open Space Forced Swim Test, a preclinical mouse model. At an oral dose of 30 mg/kg, EB-003 significantly reduced depression-like behavior within 30 minutes, showing comparable effects to Imipramine, an approved antidepressant.
The study confirmed the efficacy of the 30 mg/kg dose and revealed no adverse locomotor effects. Additionally, a 22-day daily dosing trial showed no adverse behavioral, physiological, or neurological effects, supporting its safety for long-term use. EB-003 is part of Enveric's EVM301 Series, designed to stimulate synaptic plasticity without hallucinogenic effects.
Enveric Biosciences (NASDAQ: ENVB) has filed a new provisional patent application for a family of molecules showing potential in treating neurodegenerative diseases. The molecules enhance brain-derived neurotrophic factor (BDNF) activity and target the BDNF/TrKB pathway, which supports neuroprotection and adult neurogenesis.
Initial testing revealed promising results, including promotion of neuronal development in cell-based assays. A prototype molecule demonstrated favorable pharmaceutical and pharmacokinetic characteristics, including effective oral delivery, brain penetration, and rapid plasma clearance, without showing 5HT2B receptor activation that could indicate cardiovascular risks.
The discovery could expand Enveric's market potential, targeting an estimated 50 million people worldwide affected by neurodegenerative diseases, including 7 million in the United States.
FAQ
What is the current stock price of Enveric Biosciences (ENVB)?
What is the market cap of Enveric Biosciences (ENVB)?
